Upstream Bio, Inc.

UPB Nasdaq SEC CIK 2022626
Follow Upstream Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $395K −42.2% vs same quarter last year
Net income −$41.2M −22.1% vs same quarter last year
EPS, diluted −$0.75 −19% vs same quarter last year
Operating cash flow −$54.2M −143.8% vs same quarter last year
Revenue by quarter
$613K
$566K
$937K
$683K
$668K
$1M
$773K
$395K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$2.9M−$143.4M
FY24$2.4M−$62.8M
FY23$2.4M−$20.5M
FY22--
MarginsShare of revenue
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−5618.8%−5026%
FY24−3281.2%−2650%
FY23−1685.5%−862.9%
FY22--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$133.4M
FY24−$59.7M
FY23−$38.1M
FY22-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Upstream Bio
  • Healthcare median
−6000%−4000%−2000%0%FY22FY23FY24FY25
Show the numbers
YearUpstream BioHealthcare median
FY25−5026%−30.6%
FY24−2650%−47%
FY23−862.9%−58%
FY22-−80.4%